JP5140584B2 - 抗心理社会的ストレス剤 - Google Patents
抗心理社会的ストレス剤 Download PDFInfo
- Publication number
- JP5140584B2 JP5140584B2 JP2008522302A JP2008522302A JP5140584B2 JP 5140584 B2 JP5140584 B2 JP 5140584B2 JP 2008522302 A JP2008522302 A JP 2008522302A JP 2008522302 A JP2008522302 A JP 2008522302A JP 5140584 B2 JP5140584 B2 JP 5140584B2
- Authority
- JP
- Japan
- Prior art keywords
- stress
- uridine
- social
- group
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
日本農芸化学会2006年度大会講演要旨集、発表No.2J16p01〜03、72頁
また本発明は、ウリジル酸、ウリジン又はウラシルの抗心理社会的ストレス剤製造のための使用を提供するものである。
さらに本発明は、ウリジル酸、ウリジン又はウラシルの有効量を投与することを特徴とする心理社会的ストレスの軽減、緩和、治癒する方法を提供するものである。
1.評価モデル動物の作製
げっ歯類を長期間隔離飼育(1匹/1ケージ)すると、通常の群居飼育時(8〜10匹/1ケージ)には認められない驚愕反応の亢進や攻撃性の増大の他、内分泌反応及び交感神経系の亢進が認められる。これは社会的環境や刺激を欠如させた状況下で実験動物を飼育することが一種の社会心理的ストレスとして働くためと考えられている(朝倉書店「睡眠のメカニズム」、P52〜73「ストレスと睡眠」(1997))。今回、この現象を利用しウリジン及び比較対照としてGABAの抗ストレス作用の評価を行った。具体的にはddy系雄性マウスを4週齢時より隔離飼育し社会心理的ストレス(隔離飼育ストレス)負荷を開始し、評価モデル動物を作製した。
隔離飼育ストレスモデルマウスにおいて隔離飼育期間の長さに依存して、隔離飼育マウスにおける攻撃性発現の増加が生じることがMatsumotoらにより報告されている(朝倉書店「睡眠のメカニズム」、P52〜73「ストレスと睡眠」(1997))。これを参考に以下の評価を行なった。すなわち、隔離飼育開始より6週間経過時にマウス2匹を同一ケージに20分間入れ、攻撃行動が発現している時間を測定し、攻撃行動増加に対するウリジン及びGABAの効果を検討した。
化合物は全て0.5%カルボキシメチルセルロース水溶液に懸濁又は溶解し、1日1回、週6日、実験終了時まで経口投与した。
マウスを4群に分け、1群は群居飼育とし溶媒を投与した。他の3群は隔離飼育とし、溶媒又はウリジン,GABAをそれぞれ100mg/kg/day投与した。闘争行動の測定は各群17組行なった。(n=9)
図1に示すように、通常の飼育条件である群居飼育群では闘争行動は観察されなかったが、社会心理的ストレスを負荷した隔離飼育群で闘争行動が顕著に増加した。この隔離飼育群にウリジンを投与することで異常行動が有意(***:P<0.001)に改善されることを確認した。また、比較対照としたGABA投与群においても有意(*:P<0.05)な改善作用が認められたが、その効果はウリジン投与群より劣っており、本発明の有効成分の効力は、GABAより優れたものであることが明らかとなった。
ウリジンの投与量を10mg/kg/dayに変更し、さらにウリジンの代わりにウリジル酸を用いて投与量を1g/kg/dayに設定し、実施例1と同様な実験を行った結果、図2に示すように低用量のウリジン(**:P<0.01)及びウリジル酸(*:P<0.05)のいずれのケースでも有意な改善作用が認められた。
Claims (2)
- ウリジル酸又はウリジンを単一の有効成分として含有することを特徴とする、社会的環境の変化又は社会的刺激の欠如により生じるストレスに対する抗心理社会的ストレス剤。
- ウリジル酸又はウリジンを1日当たり10〜1000mg/kg経口摂取するものである請求項1記載の抗心理社会的ストレス剤。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008522302A JP5140584B2 (ja) | 2006-06-27 | 2007-06-26 | 抗心理社会的ストレス剤 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006177094 | 2006-06-27 | ||
| JP2006177094 | 2006-06-27 | ||
| JP2008522302A JP5140584B2 (ja) | 2006-06-27 | 2007-06-26 | 抗心理社会的ストレス剤 |
| PCT/JP2007/000688 WO2008001495A1 (en) | 2006-06-27 | 2007-06-26 | Agent against psychosocial stresses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2008001495A1 JPWO2008001495A1 (ja) | 2009-11-26 |
| JP5140584B2 true JP5140584B2 (ja) | 2013-02-06 |
Family
ID=38845270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522302A Active JP5140584B2 (ja) | 2006-06-27 | 2007-06-26 | 抗心理社会的ストレス剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8017594B2 (ja) |
| EP (1) | EP2033647A4 (ja) |
| JP (1) | JP5140584B2 (ja) |
| WO (1) | WO2008001495A1 (ja) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8523851B2 (en) * | 2009-04-17 | 2013-09-03 | Domain Surgical, Inc. | Inductively heated multi-mode ultrasonic surgical tool |
| JP2011032232A (ja) * | 2009-08-04 | 2011-02-17 | Ito En Ltd | 興奮抑制用又は鎮静用組成物及びこれを含む飲食品 |
| KR20240144277A (ko) | 2022-03-01 | 2024-10-02 | 야마사 쇼유 가부시키가이샤 | Bdnf 산생 촉진제 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5867621A (ja) * | 1981-10-19 | 1983-04-22 | Nippon Zoki Pharmaceut Co Ltd | 鎮痛、鎮静剤 |
| JPS60136515A (ja) * | 1983-12-23 | 1985-07-20 | Yasuo Komoda | 睡眠促進剤 |
| JPH07215879A (ja) * | 1994-02-02 | 1995-08-15 | Otsuka Pharmaceut Factory Inc | 抗ストレス組成物 |
| JPH10203989A (ja) * | 1997-01-27 | 1998-08-04 | Yamasa Shoyu Co Ltd | 情動障害の改善剤 |
| JP2003517437A (ja) * | 1998-07-31 | 2003-05-27 | マサチューセッツ インスティテュート オブ テクノロジー | インビボでシチジンレベルを上昇させ、シチジン依存性のヒト疾患を治療するための方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050203053A1 (en) | 1999-07-30 | 2005-09-15 | Wurtman Richard J. | Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function |
| JP3394511B2 (ja) | 2000-08-31 | 2003-04-07 | 株式会社東洋新薬 | 動物飼料 |
| JP2003327528A (ja) | 2002-03-04 | 2003-11-19 | Pharmafoods Kenkyusho:Kk | 免疫能改善用組成物 |
| EP1727554A4 (en) | 2003-10-08 | 2009-09-30 | Mclean Hospital Corp | METHODS OF TREATING PSYCHIATRIC DISORDERS, ALCOHOL AND DRUG ABUSE DISORDERS, AND OTHER DISORDERS USING COMBINATIONS CONTAINING OMEGA 3 FATTY ACIDS |
| JP4656859B2 (ja) | 2004-05-19 | 2011-03-23 | 明治飼糧株式会社 | 酸化ストレス抑制剤 |
-
2007
- 2007-06-26 EP EP07790211A patent/EP2033647A4/en not_active Withdrawn
- 2007-06-26 WO PCT/JP2007/000688 patent/WO2008001495A1/ja not_active Ceased
- 2007-06-26 JP JP2008522302A patent/JP5140584B2/ja active Active
- 2007-06-26 US US12/302,044 patent/US8017594B2/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5867621A (ja) * | 1981-10-19 | 1983-04-22 | Nippon Zoki Pharmaceut Co Ltd | 鎮痛、鎮静剤 |
| JPS60136515A (ja) * | 1983-12-23 | 1985-07-20 | Yasuo Komoda | 睡眠促進剤 |
| JPH07215879A (ja) * | 1994-02-02 | 1995-08-15 | Otsuka Pharmaceut Factory Inc | 抗ストレス組成物 |
| JPH10203989A (ja) * | 1997-01-27 | 1998-08-04 | Yamasa Shoyu Co Ltd | 情動障害の改善剤 |
| JP2003517437A (ja) * | 1998-07-31 | 2003-05-27 | マサチューセッツ インスティテュート オブ テクノロジー | インビボでシチジンレベルを上昇させ、シチジン依存性のヒト疾患を治療するための方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2033647A1 (en) | 2009-03-11 |
| US20090118224A1 (en) | 2009-05-07 |
| JPWO2008001495A1 (ja) | 2009-11-26 |
| EP2033647A4 (en) | 2010-07-28 |
| WO2008001495A1 (en) | 2008-01-03 |
| US8017594B2 (en) | 2011-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2680751C (en) | Use of dioxabicyclo[3.3.0]octane derivatives as anti-fatigue agents | |
| CN101410115B (zh) | 含有核黄素和芝麻素类的组合物 | |
| JP5714227B2 (ja) | アンドログラホリドを有効成分とする抗疲労剤及び経口組成物 | |
| JP2009167195A (ja) | 抗ストレス性疾患剤 | |
| US20200289442A1 (en) | Supporting immunomodulatory agent | |
| JP2010138170A (ja) | 抗疲労組成物 | |
| JP5140584B2 (ja) | 抗心理社会的ストレス剤 | |
| ES2208330T3 (es) | Composiciones para modular la respuesta nmune y para el tratamiento de la enfermedad inflamatoria. | |
| TW202200160A (zh) | 含有nr及/或nmn與芝麻素類之組成物 | |
| JP4656859B2 (ja) | 酸化ストレス抑制剤 | |
| JP4723320B2 (ja) | 血中レプチン濃度上昇剤 | |
| JP7332489B2 (ja) | ホスホジエステラーゼ3阻害用組成物及び血小板凝集抑制用組成物 | |
| JP2007230954A (ja) | 睡眠誘導剤及びストレス性不眠症改善剤 | |
| US20200215149A1 (en) | N-Phenylacetyl-L-prolylglycine ethyl ester compositions and methods for using the same | |
| JP5110683B2 (ja) | 睡眠誘導剤、ストレス性不眠症改善剤 | |
| RU2308188C2 (ru) | Применение корма, обработанного полиферментным препаратом "гимизим", при отравлении животных и кур тяжелыми металлами | |
| WO2025045633A1 (en) | Fluralaner for use in methods of treatment and prevention of sea lice infestation in fish | |
| JP7181695B2 (ja) | 抗認知症剤及び短期記憶障害改善/抑制剤 | |
| JP2024132757A (ja) | 意欲低下の予防改善剤 | |
| CN119365190A (zh) | 交感神经活化剂和交感神经活化用组合物 | |
| JP2025154328A (ja) | 腎障害の予防用または治療用組成物 | |
| HK40089161A (zh) | 烟醯胺腺嘌呤二核苷酸(nad)浓度上升剂 | |
| RU2020136016A (ru) | Композиции и способы для перорального введения животным | |
| JP2004337107A (ja) | 動物用夜鳴き改善剤及び動物用夜鳴き改善食品 | |
| JPH03127922A (ja) | 魚類の表皮保護剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100208 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100208 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120724 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120906 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121113 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121119 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5140584 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151122 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |